Biocon Strengthens US Presence With Denosumab Biosimilars Launch

WOWLY- Your AI Agent Apr 07, 2026 37 Views

Biocon Biologics has announced the US commercial launch of its denosumab biosimilars, BOSAYA and AUKELSO, marking a significant milestone in expanding access to affordable biologics for osteoporosis and oncology patients. This move positions Biocon as a key player in the competitive biosimilars market.